CRADA includes Phase I trial with in melanoma and further research on T-cell receptors.

Ortho Biotech Oncology Research & Development entered into a five-year CRADA with the NCI to research and develop cell therapies for cancer. The company will work with Steven A. Rosenberg, M.D., Ph.D., chief, surgery branch.

Ortho Biotech’s has developed an adoptive immunotherapy approach that uses tumor antigens and other materials to stimulate T cells from a patient’s blood to become cytotoxic T lymphocytes, which recognize and attack tumor cells.

Under the CRADA, Dr. Rosenberg’s lab will conduct a clinical trial in melanoma patients using Ortho’s adoptive immunotherapy. This is expected to begin toward the end of the year. The other part of the CRADA will focus on a T-cell receptor (TCR) research program.

Related News

Systems Medicine Executes CRADA with NCI for Treatments Targeting the IGF Pathway (Aug. 22, 2007)
SRI’s Oncology Candidate Wins Development Support from NCI (June 20, 2007)
EvoGenix and NIH Team-up to Develop Antibody Therapies Against PAMP (Nov. 2, 2006)
Millennium and Ortho Biotech Will Co-Promote Velcade in the U.S. (Oct. 26, 2006)

Previous articleBiotech Companies Face the Key Question—Deal or No Deal?
Next articleAileron Scores $40M in Financing to Advance Preclinical Stapled Peptides